Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (SHA:688505) said China's state drug administrator accepted the drug application of company subsidiary Taizhou Fudan Zhangjiang Pharmaceutical.
The application was for the registration and marketing authorization of obeticholic acid tablets to treat primary biliary cholangitis, according to a Friday filing with the Shanghai bourse.
Shares of the pharmaceutical company closed 1% higher Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments